The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics

Clinical Pharmacology and Therapeutics
R Z HarrisL Z Benet

Abstract

The pharmacokinetics of oral and intravenous prednisolone and intravenous erythromycin were examined in premenopausal women, postmenopausal women not undergoing hormone replacement therapy, postmenopausal women undergoing estrogen replacement therapy, and postmenopausal women undergoing estrogen and progestin replacement therapy. The unbound clearance of prednisolone was significantly lower in postmenopausal women (11.6 +/- 2.3 ml/min/kg) than in premenopausal women (16.6 +/- 3.5 ml/min/kg). A comparable difference was also observed in total clearance and in half-life. The bioavailability and volume of distribution of prednisolone were unaffected by menopausal status. Hormone replacement therapies did not significantly affect prednisolone pharmacokinetics. In contrast to prednisolone elimination, erythromycin elimination, as measured by the erythromycin breath test, was not significantly affected by either menopausal status or hormone replacement therapy. In addition, there was no correlation between prednisolone clearance and the erythromycin breath test result. Although cytochrome P450 3A4 (CYP3A4) has been implicated in steroid hormone metabolism, these results suggest that another enzyme system, which is decreased in menopa...Continue Reading

Associated Clinical Trials

Apr 24, 2008·Kristine Patterson, MD

References

Aug 1, 1979·Journal of Pharmaceutical Sciences·L Z Benet, R L Galeazzi
Jan 1, 1992·Critical Reviews in Toxicology·S A Wrighton, J C Stevens
Dec 14, 1991·Lancet·J C KolarsP B Watkins
Jan 1, 1991·Methods in Enzymology·H W StrobelJ W white
Dec 1, 1991·Journal of Pharmaceutical Sciences·M C EtienneM Namer
Jul 1, 1991·Clinical Pharmacokinetics·A Rubio, C Cox
Nov 1, 1990·Clinical Pharmacokinetics·H J LemmensJ G Bovill
Jan 1, 1986·The Journal of Clinical Endocrinology and Metabolism·L E GustavsonL Z Benet
Nov 1, 1988·Journal of Clinical Pharmacology·A A HolazoI H Patel
Apr 1, 1988·Clinical Pharmacology and Therapeutics·A E StuckF J Frey
Dec 1, 1984·Clinical Pharmacology and Therapeutics·R L MilsapW J Jusko
Apr 1, 1984·British Journal of Clinical Pharmacology·P J MeffinB C Sallustio
Mar 1, 1995·Toxicologic Pathology·L Z Benet, P Zia-Amirhosseini
Sep 1, 1994·Clinical Pharmacology and Therapeutics·D K TurgeonP B Watkins
May 1, 1994·Experimental Gerontology·L E Gustavson, L Z Benet
Aug 1, 1994·Pharmacogenetics·P B Watkins
Oct 1, 1993·Clinical Pharmacology and Therapeutics·K H LewW J Jusko

❮ Previous
Next ❯

Citations

Jan 28, 2004·Annual Review of Pharmacology and Toxicology·Monica GandhiTerrence F Blaschke
Apr 24, 2009·Clinical Pharmacokinetics·Offie P Soldin, Donald R Mattison
Mar 16, 2011·Journal of Biomedicine & Biotechnology·Offie P SoldinDonald R Mattison
Oct 31, 2008·Clinical Pharmacology and Therapeutics·Mj Kennedy
May 17, 2015·HIV Clinical Trials·Cynthia FirnhaberThomas B Campbell
Jul 18, 2006·British Journal of Clinical Pharmacology·Stéphane MoulyJean-François Bergmann
Sep 19, 2006·Cutaneous and Ocular Toxicology·Bobeck S ModjtahediHoward I Maibach
Jun 5, 2008·Expert Opinion on Drug Metabolism & Toxicology·Marissa J ScandlynRhonda J Rosengren
Mar 7, 2017·Transplantation Reviews·Jeremiah D MomperDianne B McKay
Nov 8, 2008·Journal of Pediatric Hematology/oncology·Marie Louise DavidsenKjeld Schmiegelow
Apr 2, 2010·Therapeutic Drug Monitoring·Jackson K MukonzoEleni Aklillu
Jan 27, 2006·European Journal of Drug Metabolism and Pharmacokinetics·Sermin OztekinTugba Gurpinar
Jan 7, 2005·Clinical Pharmacokinetics·Monette M CotreauDavid J Greenblatt
Jan 20, 2005·Clinical Pharmacokinetics·Tony Antoniou, Alice L Tseng
Jul 30, 2004·The Journal of Pharmacology and Experimental Therapeutics·Eric T WilliamsHenry W Strobel
Mar 23, 2011·European Journal of Haematology·Louise BorstKjeld Schmiegelow
Apr 24, 2003·Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics·Yusuke Tanigawara
Dec 20, 2019·BMC Pharmacology & Toxicology·João Paulo Bianchi XimenezVera Lucia Lanchote
May 21, 2021·Advanced Drug Delivery Reviews·Christine M MadlaAbdul W Basit
Nov 20, 2021·European Geriatric Medicine·Felix Stader, Catia Marzolini

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Clinical Pharmacology and Therapeutics
J C GorskiS D Hall
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis
Petra Jilma-StohlawetzBernd Jilma
© 2021 Meta ULC. All rights reserved